Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Cyclerion Therapeutics (CYCN) over the last 5 years, with Q3 2025 value amounting to $3.2 million.

  • Cyclerion Therapeutics' Shares Outstanding (Diluted Average) rose 2767.22% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 2767.22%. This contributed to the annual value of $2.5 million for FY2024, which is 769.89% up from last year.
  • Latest data reveals that Cyclerion Therapeutics reported Shares Outstanding (Diluted Average) of $3.2 million as of Q3 2025, which was up 2767.22% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Cyclerion Therapeutics' Shares Outstanding (Diluted Average) registered a high of $43.3 million during Q3 2021, and its lowest value of $43425.0 during Q1 2022.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $8.5 million, with a median of $2.5 million in 2024.
  • In the last 5 years, Cyclerion Therapeutics' Shares Outstanding (Diluted Average) crashed by 9497.82% in 2022 and then soared by 491093.84% in 2023.
  • Cyclerion Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $39.1 million in 2021, then plummeted by 94.45% to $2.2 million in 2022, then rose by 7.59% to $2.3 million in 2023, then rose by 7.7% to $2.5 million in 2024, then rose by 28.08% to $3.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $3.2 million for Q3 2025, versus $3.1 million for Q2 2025 and $2.6 million for Q1 2025.